Capital Rx announced the close of its $106M Series C funding led by B Capital, with participation from General Catalyst and existing investors, Transformation Capital and Edison Partners
Capital Rx is finding success in its mission to disrupt the traditional pharmacy benefits model and help employers gain more control over their prescription drug costs
Through its Clearinghouse Model, Capital Rx unlocks the pharmacy supply chain and reduces prescription costs for employer groups
Capital Rx works to increase cost transparency and consistency for its clients by using the government-maintained National Average Drug Acquisition Cost database, which aims to provide accurate, upfront costs of drugs across pharmacies to health plans